Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 57,500 shares of the common stock of the Company to three newly hired non-officer employees, with a per share exercise price of $12.86, the closing trading price on the grant date. A Senior Vice President was also granted an option to purchase 100,000 shares of the Company’s common stock, with a per share exercise price of $12.86, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company. About C
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]Yahoo! Finance
- Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025GlobeNewswire
- Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases [Yahoo! Finance]Yahoo! Finance
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target raised by analysts at Robert W. Baird from $4.00 to $6.00. They now have an "outperform" rating on the stock.MarketBeat
CHRS
Earnings
- 11/6/24 - Beat
CHRS
Sec Filings
- 12/17/24 - Form 4
- 12/4/24 - Form 8-K
- 12/4/24 - Form DEFA14A
- CHRS's page on the SEC website